CompletedNCT01199315
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses
Medication studyAges 20–80JapanADHD
Understand this study
Who was this study for?
Listed age limits: 20 years to 80 years.
- Listed locations
- FukuokaSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateSeptember 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Japan
- Age range
- From 20 Years to 80 Years
- Official registry ID
- NCT01199315
- Official title
Show the full official title
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 in Young and Elderly Healthy Japanese Volunteers After Oral Single and Repeated Doses
Get this study by email
Recruitment & locations
CompletedFukuoka
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including AZD1446 and Placebo.
Who was this study for?
Listed age limits: 20 years to 80 years.
